billHR6130•Event Wednesday, November 19, 2025Analyzed

ASAP Act

Bullish

Impact5/10

Summary

The ASAP Act, HR6130, mandates Medicare coverage for blood-based dementia screening tests starting January 1, 2028, creating a new market for diagnostic companies. The bill is in the early stages of the legislative process, having been referred to two House committees. Companies with existing or developing FDA-approved blood-based diagnostic platforms stand to benefit from this potential market expansion.

Key Takeaways

1.The ASAP Act mandates Medicare coverage for blood-based dementia screening tests starting January 1, 2028.
2.This creates a new, substantial market for diagnostic companies with FDA-approved blood tests for Alzheimer's and related dementias.
3.The bill is in the early stages of the legislative process, having been referred to two House committees, but has a companion bill in the Senate.

Market Implications

The potential passage of the ASAP Act represents a significant long-term market opportunity for diagnostic companies. By mandating Medicare coverage, the bill would establish a broad patient base for blood-based dementia screening tests, driving demand and revenue growth for companies like Labcorp Holdings Inc. ($LH) and Quest Diagnostics Incorporated ($DGX). These companies, with their established diagnostic infrastructure, are well-positioned to capitalize on this new market segment. QuidelOrtho Corporation ($QDEL) and Revvity, Inc. ($RVTY) could also see increased demand for their diagnostic platforms and related technologies if they develop or acquire FDA-approved tests that meet the bill's criteria. While the bill is in its early legislative phase, its progression would structurally enhance the total addressable market for dementia diagnostics. Current market trends for these companies, such as $LH's recent 7-day gain of +4.12% to $274.46 and $DGX's current price of $198.96, are not directly tied to this specific bill's status but reflect broader market dynamics. However, successful passage would provide a clear, long-term growth catalyst for the sector, potentially influencing future valuations.

Full Analysis

The ASAP Act (H.R. 6130), introduced on November 19, 2025, aims to amend the Social Security Act to provide Medicare coverage for blood-based dementia screening tests. This bill is currently in the early stages of the legislative process, having been referred to the House Committee on Energy and Commerce and the House Committee on Ways and Means. A companion bill, S3267, has also been introduced in the Senate, indicating bipartisan and bicameral interest in the policy. The bill does not authorize a specific dollar amount but rather mandates a new coverage category under Medicare. This means that once enacted, Medicare will cover the costs of FDA-approved blood-based dementia screening tests, effectively creating a new, substantial revenue stream for diagnostic companies. The funding mechanism is through Medicare payments for covered services, rather than a direct appropriation or grant program. The bill specifies that coverage would begin on January 1, 2028, for tests cleared, classified, or approved by the FDA. Structural winners include companies that develop and commercialize FDA-approved blood-based diagnostic platforms for Alzheimer's and related dementias. This directly benefits companies like Labcorp Holdings Inc. ($LH) and Quest Diagnostics Incorporated ($DGX), which have extensive diagnostic testing capabilities and infrastructure. QuidelOrtho Corporation ($QDEL) and Revvity, Inc. ($RVTY), which are involved in diagnostic solutions and life sciences, are also positioned to benefit if they develop or acquire relevant FDA-approved tests. The bill's broad definition of eligible tests, including genomic sequencing blood tests and other equivalent tests, suggests a wide range of diagnostic technologies could be covered. Based on recent market data, Labcorp Holdings Inc. ($LH) is currently trading at $274.46, showing a 7-day change of +4.12% and a 30-day change of -0.53%. Quest Diagnostics Incorporated ($DGX) is at $198.96, with a 7-day change of +0.91% and a 30-day change of -2.46%. QuidelOrtho Corporation ($QDEL) is at $15.88, with a 7-day change of +4.06% but a 30-day change of -25.83%. Revvity, Inc. ($RVTY) is at $88.32, with a 7-day change of +4.18% and a 30-day change of -8.54%. The bill's early stage means current market movements are not directly attributable to its potential passage, but the long-term outlook for these companies could be positively impacted if the bill progresses. For the bill to become law, it must pass both the House and the Senate and then be signed by the President. Given its current status of being referred to two House committees and having a companion bill in the Senate, it has initiated the legislative process but has several steps remaining, including committee review, potential amendments, floor votes, and reconciliation between chambers if differences arise.